Multidisciplinary Centre for Advanced Research and Studies, Jamia Millia Islamia, New Delhi, India.
Front Cell Infect Microbiol. 2021 Feb 24;10:628257. doi: 10.3389/fcimb.2020.628257. eCollection 2020.
Amebiasis is a neglected tropical disease which is caused by the protozoan parasite . This disease is one of the leading causes of diarrhea globally, affecting largely impoverished residents in developing countries. Amebiasis also remains one of the top causes of gastrointestinal diseases in returning international travellers. Despite having many side effects, metronidazole remains the drug of choice as an amebicidal tissue-active agent. However, emergence of metronidazole resistance in pathogens having similar anaerobic metabolism and also in laboratory strains of has necessitated the identification and development of new drug targets and therapeutic strategies against the parasite. Recent research in the field of amebiasis has led to a better understanding of the parasite's metabolic and cellular pathways and hence has been useful in identifying new drug targets. On the other hand, new molecules effective against amebiasis have been mined by modifying available compounds, thereby increasing their potency and efficacy and also by repurposing existing approved drugs. This review aims at compiling and examining up to date information on promising drug targets and drug molecules for the treatment of amebiasis.
溶组织内阿米巴病是一种被忽视的热带病,由原生动物寄生虫引起。这种疾病是全球腹泻的主要原因之一,主要影响发展中国家的贫困居民。溶组织内阿米巴病也是返回国际旅行者中胃肠道疾病的主要原因之一。尽管甲硝唑有许多副作用,但它仍然是作为一种杀组织活性药物的首选药物。然而,具有相似厌氧代谢的病原体和 的实验室菌株中甲硝唑耐药性的出现,使得有必要针对寄生虫确定和开发新的药物靶点和治疗策略。溶组织内阿米巴病领域的最新研究使人们对寄生虫的代谢和细胞途径有了更好的了解,因此有助于确定新的药物靶点。另一方面,通过修饰现有化合物,或者通过重新利用现有的批准药物,已经挖掘出了针对溶组织内阿米巴病有效的新分子。本综述旨在汇集和检查有关溶组织内阿米巴病治疗的有前途的药物靶点和药物分子的最新信息。